Viewing Study NCT06651151

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:55 PM
Ignite Modification Date: 2026-03-09 @ 7:21 AM
Study NCT ID: NCT06651151
Status: RECRUITING
Last Update Posted: 2024-10-26
First Post: 2024-10-18
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Sponsor: Oslo University Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma Stage IIIB-IV View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Melanoma View
None Neoadjuvant View
None Pembrolizumab View
None Oncolytic peptide View